Surgical ML Leader Ceevra is FDA-cleared and CE Marked for all surgeries and became the first company cleared by the FDA to use ML for generating 3D images in urologic and thoracic surgical planning, indicating strong regulatory credibility and potential expansion into additional high-value surgical segments.

High Impact Use Their 3D patient-specific models have supported over 5,000 procedures, suggesting proven clinical utility and compelling case studies for adoption by hospitals and surgical centers seeking organ preservation, shorter hospital stays, and reduced cancer recurrence risk.

Enterprise Growth With a focused team size (11-50 employees) and annual revenue in the low to mid multi-millions range, there is room for channel partnerships, integrator deals, and scaled sales to mid-market and large hospital systems through strategic partnerships.

Tech & Compliance Operating with ISO 13485 quality management and a stack including MySQL, React, PHP, and cloud and security tooling, Ceevra appeals to procurement-minded buyers prioritizing compliance, data integrity, and scalable integration with existing imaging workflows.

Upsell Opportunities The company’s emphasis on ML-driven 3D imaging for planning across multiple surgical domains opens cross-sell potential to additional specialties, clinical departments, and long-term service agreements with hospitals investing in standardized, repeatable 3D planning capabilities.